AMYGDALA NEUROSCIENCES, INC.

Palo Alto, CA · Founded 2015 · CIK 0001640814 · Biotech · Private

Selective, reversible ALDH2 inhibitor small-molecule therapeutic for alcohol use disorder

Grants
$225K
1 award
Sector median: 1
Raised
$7.0M
2 Form D · Nov 2019
82 months since last filing
Contracts
—
No federal contracts on record
Patents
21
5 granted · 16 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,449,990
Private capital raisedForm D · SEC$5,594,783
Federal grantDepartment of Health and Human Services · Phase I · Discovery next generation inhibitors of ALDH2 to reduce craving and alcohol consumption in alcohol use disorders$224,500
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2491CELL DATA SCIENCES, INC.——
2492Cerevel Therapeutics——
2493BIOMARCK PHARMACEUTICALS, LTD—$8.0M
2494AMYGDALA NEUROSCIENCES, INC.—$7.0M
2495Cirrus Therapeutics, Inc.—$6.7M
2496Semnur Pharmaceuticals, Inc.—$6.0M
2497b3 bio, inc.—$5.7M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Ivan DiamondDirector · Executive Officer
  • Howard JaffeDirector
  • Louis LangeDirector
  • William LeeDirector
  • Adrienne MacMillanExecutive Officer
  • Mack Mitchell, Jr.Director
  • Peter StrumphDirector · Executive Officer

Patents

USPTO · 5 granted of 21

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.